Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma

Published on 17 Feb 2025
Last Updated on 17 Feb 2025

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended durvalumab in combination with tremelimumab for inclusion on the MOH List of Subsidised Drugs for treating unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy. The decision for durvalumab in combination with tremelimumab was based on its unfavourable cost effectiveness versus sorafenib, its uncertain clinical and cost effectiveness versus atezolizumab plus bevacizumab, and the unacceptable price-volume agreements proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for durvalumab plus tremelimumab are provided in the Annex.

Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma (17 Feb 2025) [PDF, 205 KB]

PES Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma (17 Feb 2025) [PDF, 59 KB]